Effects of pioglitazone vs glimepiride on coronary arterial inflammation in patients with type 2 diabetes mellitus or impaired glucose tolerance

Trial Profile

Effects of pioglitazone vs glimepiride on coronary arterial inflammation in patients with type 2 diabetes mellitus or impaired glucose tolerance

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2012

At a glance

  • Drugs Pioglitazone (Primary) ; Glimepiride
  • Indications Atherosclerosis; Glucose intolerance; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 28 Nov 2012 New trial record
    • 07 Nov 2012 Results assessing the effects of treatment on volume and glucose metabolism of visceral fat presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top